{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:52:59Z","timestamp":1791211979080,"version":"4.1.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Suppl 3","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:p>Diabetic macular edema (DME) is a common microvascular complication of diabetes and a major cause of vision impairment. Intravitreal vascular endothelial growth factor (VEGF) inhibitors remain the gold standard for its management. However, the high cost and limited accessibility of reference anti-VEGF agents have driven growing interest in biosimilars\u2014biologic therapies designed to match the efficacy, safety, and immunogenicity of their reference products. Following the expiration of patents for agents such as aflibercept and ranibizumab, several biosimilars have been developed, approved, and introduced into clinical practice. Evidence from real-world studies\u2014including RE-ENACT2 (REal-life assessmENt of safety And effeCTiveness of Razumab) and REAR-RD2 (REal-world observational study to evaluate the risk factors in the management of REtinal Diseases-2)\u2014as well as randomized clinical trials such as INSIGHT and CT-P42 has demonstrated clinical equivalence between these biosimilars and their reference anti-VEGF counterparts in the treatment of DME. This article provides an updated overview of the current evidence base, recent advances in regulatory pathways, and ongoing challenges in integrating biosimilars into routine DME management.<\/jats:p>","DOI":"10.4103\/ijo.ijo_3330_25","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T15:00:12Z","timestamp":1790953212000},"page":"S345-S352","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Biosimilars in diabetic macular edema: Promise, progress, and pitfalls"],"prefix":"10.4103","volume":"74","author":[{"given":"Vanaja","family":"Jain","sequence":"first","affiliation":[{"name":"Anant Bajaj Retina Institute, Kallam Anji Reddy Campus, LV Prasad Eye Institute, Hyderabad, Telangana, India"},{"name":"Standard Chartered-LVPEI Academy for Eye Care Education, Kallam Anji Reddy Campus, LV Prasad Eye Institute, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek P","family":"Dave","sequence":"additional","affiliation":[{"name":"Anant Bajaj Retina Institute, Kallam Anji Reddy Campus, LV Prasad Eye Institute, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj P","family":"Shettigar","sequence":"additional","affiliation":[{"name":"Anant Bajaj Retina Institute, Y S Rajasekhara Reddy Campus, LV Prasad Eye Institute, Kadapa, Andhra Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-Kuang","family":"Hwang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Taipei Veterans General Hospital, National Yang Ming Chiao Tung University, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibel","family":"Demirel","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Ankara University, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"key":"R1-20261005","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.ophtha.2021.04.027","article-title":"Global prevalence of diabetic retinopathy and projection of burden through 2045","volume":"128","author":"Teo","year":"2021","journal-title":"Ophthalmology"},{"key":"R2-20261005","first-page":"447","article-title":"An overview on Anti-Vegf and in search for an ideal anti VEGF agent","volume":"8","author":"Abdur-Rahman","year":"2022","journal-title":"Int J Exp Res Rev"},{"key":"R3-20261005","doi-asserted-by":"crossref","first-page":"632307","DOI":"10.1155\/2014\/632307","article-title":"Anti-VEGF for the management of diabetic macular edema","volume":"2014","author":"Stefanini","year":"2014","journal-title":"J Immunol Res"},{"key":"R4-20261005","first-page":"253","article-title":"Real-world injection frequency and cost of ranibizumab and aflibercept for the treatment of neovascular age-related macular degeneration and diabetic macular edema","volume":"26","author":"Kiss","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"key":"R5-20261005","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40942-021-00343-3","article-title":"Future of anti-VEGF: Biosimilars and biobetters","volume":"8","author":"Kapur","year":"2022","journal-title":"Int J Retin Vitr"},{"key":"R6-20261005","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3390\/pharmaceutics16030321","article-title":"A regulatory perspective on biosimilar medicines","volume":"16","author":"Cordeiro","year":"2024","journal-title":"Pharmaceutics"},{"key":"R7-20261005","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3928\/23258160-20230508-01","article-title":"Biosimilars in the treatment of retinal disease in the United States","volume":"54","author":"Vakharia","year":"2023","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R11-20261005","doi-asserted-by":"crossref","first-page":"107224","DOI":"10.1016\/j.ejps.2025.107224","article-title":"Biosimilars and interchangeability: Regulatory, scientific, and global perspectives","volume":"213","author":"Iskit","year":"2025","journal-title":"Eur J Pharm Sci"},{"key":"R14-20261005","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s10295-019-02216-z","article-title":"Current perspectives on biosimilars","volume":"46","author":"Agbogbo","year":"2019","journal-title":"J Ind Microbiol Biotechnol"},{"key":"R15-20261005","doi-asserted-by":"crossref","first-page":"105501","DOI":"10.1016\/j.ejps.2020.105501","article-title":"Reporting of quality attributes in scientific publications presenting biosimilarity assessments of (intended) biosimilars: A systematic literature review","volume":"154","author":"Alsamil","year":"2020","journal-title":"Eur J Pharm Sci"},{"key":"R16-20261005","article-title":"Guidelines on Similar Biologics: Regulatory Requirements for Marketing Authorization in India","year":"2025"},{"key":"R18-20261005","doi-asserted-by":"crossref","first-page":"347","DOI":"10.4103\/ijo.IJO_2516_20","article-title":"Clinical efficacy and safety of Razumab\u00ae (CESAR) study: Our experience with the world\u2019s first biosimilar ranibizumab","volume":"69","author":"Verma","year":"2021","journal-title":"Indian J Ophthalmol"},{"key":"R19-20261005","doi-asserted-by":"crossref","first-page":"101358","DOI":"10.1016\/j.ajoc.2022.101358","article-title":"Ranizurel safety evaluation in real-world -(RaSER) study","volume":"25","author":"Sharma","year":"2022","journal-title":"Am J Ophthalmol Case Rep"},{"key":"R20-20261005","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1177\/24741264251322213","article-title":"Biosimilar ranibizumab (ranieyes) safety and efficacy in the real world: BRESER study","volume":"9","author":"Sharma","year":"2025","journal-title":"J Vitreoretin Dis"},{"key":"R21-20261005","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1167\/tvst.13.7.17","article-title":"Real-world use of off-label MVASI in the treatment of patients with neovascular AMD and DME","volume":"13","author":"Lombardo","year":"2024","journal-title":"Trans Vis Sci Tech"},{"key":"R22-20261005","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1001\/jamaophthalmol.2024.3458","article-title":"Aflibercept biosimilar MYL-1701P vs reference aflibercept in diabetic macular edema: The INSIGHT randomized clinical trial","volume":"142","author":"Bressler","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"R27-20261005","doi-asserted-by":"crossref","first-page":"248","DOI":"10.4103\/ijp.ijp_58_24","article-title":"Efficacy, safety, and cost-effectiveness of biosimilars of bevacizumab in n\u00e4ive patients with diabetic macular edema","volume":"56","author":"Virani","year":"2024","journal-title":"Indian J Pharmacol"},{"key":"R28-20261005","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1001\/jamaophthalmol.2022.5543","article-title":"Biosimilar ranibizumab and innovator ranibizumab\u2014immunogenicity assessment and its impact on safety and efficacy","volume":"141","author":"Sharma","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"R29-20261005","first-page":"15","article-title":"A multicenter, retrospective study (RE-ENACT 2) on the use of RazumabTM (World\u2019s first biosimilar ranibizumab) in Wet AMD, DME, RVO and Myopic CNV","volume":"10","author":"Sharma","year":"2019","journal-title":"J Clin Exp Ophthalmol"},{"key":"R30-20261005","doi-asserted-by":"crossref","first-page":"255","DOI":"10.18203\/2349-3259.ijct20222610","article-title":"Long-term efficacy and safety of RazumabTM (biosimilar ranibizumab) in Indian patients with retinal diseases: Results from retrospective REAR RD-2 study","volume":"9","author":"Sharma","year":"2022","journal-title":"Int J Clin Trials"},{"key":"R31-20261005","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.2147\/OPTH.S500912","article-title":"Transitioning from aflibercept to biosimilar ranibizumab in diabetic macular edema (DME): (The TRANSFORM-DME Trial) a multicenter observational study","volume":"18","author":"Chakraborty","year":"2024","journal-title":"Clin Ophthalmol"},{"key":"R32-20261005","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.oret.2024.06.013","article-title":"Biosimilar candidate CT-P42 in diabetic macular edema","volume":"8","author":"Wolf","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"R33-20261005","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1080\/10543406.2024.2330217","article-title":"Utility of real-world evidence in biosimilar development","volume":"34","author":"Arani","year":"2024","journal-title":"J Biopharm Stat"},{"key":"R34-20261005","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s40123-022-00463-5","article-title":"Comparison of innovator vs. biosimilar ranibizumab in treating diabetic macular edema: A multicenter retrospective study","volume":"11","author":"Chakraborty","year":"2022","journal-title":"Ophthalmol Ther"},{"key":"R35-20261005","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1177\/24741264231202080","article-title":"Biosimilar to biosimilar anti-VEGF switching for retinal diseases","volume":"7","author":"Sharma","year":"2023","journal-title":"J Vitreoretin Dis"},{"key":"R36-20261005","doi-asserted-by":"crossref","first-page":"100173","DOI":"10.1016\/j.jfop.2025.100173","article-title":"Intravitreal Stivant\u00ae (a biosimilar to bevacizumab) alone versus combined with triamcinolone in center-involved diabetic macular edema","volume":"11","author":"Daneshtalab","year":"2025","journal-title":"JFO Open Ophthalmol"},{"key":"R37-20261005","doi-asserted-by":"crossref","first-page":"124","DOI":"10.52756\/ijerr.2023.v32.010","article-title":"A retrospective, non-randomized, clinical review on the effect of single-dose biosimilar Razumab injection in diabetic macular edema","volume":"32","author":"Balasubramanian","year":"2023","journal-title":"International Journal of Experimental Research and Review"},{"key":"R38-20261005","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/ceo.13706","article-title":"Impact of out\u2010of\u2010pocket costs on patient initiation, adherence and persistence rates for patients treated with anti\u2010vascular endothelial growth factor medicines","volume":"48","author":"Jackson","year":"2020","journal-title":"Clin Exp Ophthalmol"},{"key":"R39-20261005","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1097\/IAE.0000000000003626","article-title":"Anti\u2013vascular endothelial growth factor biosimilars in ophthalmology","volume":"42","author":"Kaiser","year":"2022","journal-title":"Retina"},{"key":"R40-20261005","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2147\/DDDT.S457303","article-title":"Ranibizumab biosimilars in treating retinal disorders: A cost-effective revolution?","volume":"18","author":"Chatzimichail","year":"2024","journal-title":"Drug Des Devel Ther"},{"key":"R41-20261005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.25259\/IHOPEJO_1_2024","article-title":"Significant reduction in the cost of care for retinal diseases in India due to the approval of biosimilars: Lessons for health systems","volume":"3","author":"Narayanan","year":"2024","journal-title":"IHOPE J Ophthalmol"},{"key":"R42-20261005","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.ophtha.2023.04.019","article-title":"The biosimilar paradox","volume":"130","author":"Zhang","year":"2023","journal-title":"Ophthalmology"},{"key":"R43-20261005","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1016\/j.ophtha.2023.07.019","article-title":"The biosimilar paradox: How anti-VEGF biosimilars will increase patient and overall healthcare costs (Ophthalmology. 2023;130:966-973)","volume":"130","author":"Sharma","year":"2023","journal-title":"Ophthalmology"},{"key":"R44-20261005","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1080\/14712598.2023.2176218","article-title":"Biosimilars for retinal diseases: United States-Europe awareness survey (Bio-USER \u2013 survey)","volume":"23","author":"Sharma","year":"2023","journal-title":"Expert Opin Biol Ther"},{"key":"R45-20261005","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1038\/s41433-019-0722-6","article-title":"Need of education on biosimilars amongst ophthalmologists: Combating the nocebo effect","volume":"34","author":"Sharma","year":"2020","journal-title":"Eye (Lond)"},{"key":"R46-20261005","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s40123-021-00362-1","article-title":"Treatment landscape of macular disorders in indian patients with the advent of RazumabTM (World\u2019s first biosimilar ranibizumab): A comprehensive review","volume":"10","author":"Sharma","year":"2021","journal-title":"Ophthalmol Ther"},{"key":"R47-20261005","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s40290-024-00541-y","article-title":"Mitigating the nocebo effect in biosimilar use and switching: A systematic review","volume":"38","author":"Car","year":"2024","journal-title":"Pharm Med"},{"key":"R48-20261005","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/17469899.2022.2152005","article-title":"Emerging biosimilars for retinal diseases","volume":"17","author":"Sharma","year":"2022","journal-title":"Exp Rev Ophthalmol"},{"key":"R49-20261005","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s40123-022-00488-w","article-title":"An introduction to biosimilars for the treatment of retinal diseases: A narrative review","volume":"11","author":"Hariprasad","year":"2022","journal-title":"Ophthalmol Ther"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_3330_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:01:24Z","timestamp":1791208884000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_3330_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":39,"journal-issue":{"issue":"Suppl 3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_3330_25","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"2025-12-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}